Wellcome Trust Launches £200 million “Evergreen” Investment Fund
This article was originally published in The Pink Sheet Daily
Britain’s charitable foundation The Wellcome Trust has formally launched a £200 million ($325 million) fund that will invest in both early and growth-stage companies, taking a long-term view and focused initially on opportunities in the UK, Europe and on the U.S East Coast.
You may also be interested in...
The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.
The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.
The U.K.’s largest charitable foundation for biomedical research is the sole investor in a new fund that will target start-ups as well as later-stage growth opportunities across the health care spectrum.